The patent EP3697887B1 was granted on Apr 6, 2022 by Regeneron Pharmaceuticals, Inc. The patent is currently Revoked.
The table below shows 2 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.
The table below shows the patents of Regeneron Pharmaceuticals, Inc. that have been opposed by other companies.
The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.
Date
Description
Get instant alerts for new documents